Citigroup
TXMD icon

Citigroup’s TherapeuticsMD TXMD Stock Holding History

Citigroup’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,308
Closed -$79K – 7402
2020
Q4 		$79K Sell
1,308
-1,932
-60% -$132K ﹤0.01% 5730
2020
Q3 		$256K Buy
3,240
+1,936
+148% +$154K ﹤0.01% 4430
2020
Q2 		$82K Buy
1,304
+1,252
+2,408% +$72.9K ﹤0.01% 5741
2020
Q1 		$3K Sell
52
-880
-94% -$87.3K ﹤0.01% 7389
2019
Q4 		$113K Sell
932
-946
-50% -$136K ﹤0.01% 5669
2019
Q3 		$341K Buy
1,878
+58
+3% +$8.18K ﹤0.01% 4697
2019
Q2 		$237K Buy
1,820
+130
+8% +$23.3K ﹤0.01% 5109
2019
Q1 		$412K Buy
1,690
+572
+51% +$151K ﹤0.01% 4386
2018
Q4 		$213K Sell
1,118
-370
-25% -$90.2K ﹤0.01% 4966
2018
Q3 		$488K Sell
1,488
-388
-21% -$119K ﹤0.01% 4307
2018
Q2 		$585K Buy
1,876
+1,142
+156% +$349K ﹤0.01% 3924
2018
Q1 		$179K Buy
734
+280
+62% +$78.5K ﹤0.01% 5077
2017
Q4 		$137K Buy
454
+298
+191% +$83K ﹤0.01% 5365
2017
Q3 		$41K Buy
+156
New +$45.1K ﹤0.01% 6099

Other funds holding TXMD

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citigroup's TXMD Position: Q1 2026 in Review

Citigroup sold out of TherapeuticsMD (TXMD) in Q1 2026, closing a stake of 1 share — an estimated $2 sold.

Citigroup first reported a position in TXMD in Q2 2013 and held it in 40 quarters. The position peaked at $1.56M in Q1 2021. 49 funds tracked by Wall St. Rank hold TXMD as of Q1 2026.

  • Citigroup reported no remaining TherapeuticsMD position as of Q1 2026 after selling out during the quarter.
  • Citigroup sold 1 TherapeuticsMD share in Q1 2026, an estimated $2.
  • Citigroup first reported a position in TherapeuticsMD in Q2 2013 and held it in 40 quarters.
  • Citigroup's TherapeuticsMD position peaked at $1.56M in Q1 2021.
  • 49 funds tracked by Wall St. Rank held TherapeuticsMD as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.